Evidence map›Paper›PMID 27686001›Full record

ReviewEpigenomics2016

Aberrant DNA methylations in chondrosarcoma.

Pei Liu, Jacson K Shen, Jianzhong Xu, Carol A Trahan, Francis J Hornicek, Zhenfeng Duan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Epigenomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Epigenetic Abnormalities in Chondrosarcoma.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Epigenetics of Skeletal Diseases.Current osteoporosis reports · 2018
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Pei LiuSarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital & Harvard Medical School, 55 Fruit Street, Jackson 1115, Boston, MA 02114, USA.
Jacson K ShenSarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital & Harvard Medical School, 55 Fruit Street, Jackson 1115, Boston, MA 02114, USA.
Jianzhong XuDepartment of Orthopaedic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, People's Republic of China.
Carol A TrahanSarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital & Harvard Medical School, 55 Fruit Street, Jackson 1115, Boston, MA 02114, USA.
Francis J HornicekSarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital & Harvard Medical School, 55 Fruit Street, Jackson 1115, Boston, MA 02114, USA.
Zhenfeng DuanSarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital & Harvard Medical School, 55 Fruit Street, Jackson 1115, Boston, MA 02114, USA.
Harvard University · USFirst Affiliated Hospital of Zhengzhou University · CNMassachusetts General Hospital · US

Funding

COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCEU01CA151452 · NCI · NORTHEASTERN UNIVERSITY · PI AMIJI, MANSOOR M., DUAN, ZHENFENG · 2010 to 2014
$2.1M
NCI NIH HHS U01 CA151452
6 · The paper itself

Abstract

Chondrosarcoma (CS) is the second most common primary malignant bone tumor. Unlike other bone tumors, CS is highly resistant to conventional chemotherapy and radiotherapy, thus resulting in poor patient outcomes. There is an urgent need to establish alternative therapies for CS. However, the etiology and pathogenesis of CS still remain elusive. Recently, DNA methylation-associated epigenetic changes have been found to play a pivotal role in the initiation and development of human cancers, including CS, by regulating target gene expression in different cellular pathways. Elucidating the mechanisms of DNA methylation alteration may provide biomarkers for diagnosis and prognosis, as well as novel treatment options for CS. We have conducted a critical review to summarize the evidence regarding aberrant DNA methylation patterns as diagnostic biomarkers, predictors of progression and potential treatment strategies in CS.

Indexed as

DNA MethylationAnimalsBiomarkers, TumorBone NeoplasmsChondrosarcomaDNA Modification MethylasesEpigenesis, GeneticHumansBiomarkers, TumorDNA Modification Methylases5-aza-2′-deoxycytidine5-azacytidinechondrosarcomaDNA methylationepigenetics

Identifiers

PMID27686001
PMCPMC5289043
OpenAlexW2526981126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.